| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’
|
Schöffski, P.
|
|
|
30 |
2 |
p. 344
|
artikel
|
| 2 |
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
|
Parseghian, C.M.
|
|
|
30 |
2 |
p. 243-249
|
artikel
|
| 3 |
Associations of early life and adulthood adiposity with risk of epithelial ovarian cancer
|
Huang, T.
|
|
|
30 |
2 |
p. 303-309
|
artikel
|
| 4 |
Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases
|
Seoane, J.
|
|
|
30 |
2 |
p. 211-218
|
artikel
|
| 5 |
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping
|
Zugazagoitia, J.
|
|
|
30 |
2 |
p. 290-296
|
artikel
|
| 6 |
Comment on the paper ‘Boffetta et al. Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy. Ann Oncol 2018; 29(2): 484–489’
|
Consonni, D.
|
|
|
30 |
2 |
p. 340-341
|
artikel
|
| 7 |
Disclosure—in the blink of an eye
|
Tannock, I.F.
|
|
|
30 |
2 |
p. 169-170
|
artikel
|
| 8 |
Editorial board
|
|
|
|
30 |
2 |
p. ii-iii
|
artikel
|
| 9 |
Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
|
Heinhuis, K.M.
|
|
|
30 |
2 |
p. 219-235
|
artikel
|
| 10 |
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: the role of vimentin expression
|
Bronte, G.
|
|
|
30 |
2 |
p. 339-340
|
artikel
|
| 11 |
Exaggeration of PFS by blinded, independent, central review (BICR)
|
Stone, A.
|
|
|
30 |
2 |
p. 332-338
|
artikel
|
| 12 |
Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer
|
Siravegna, G.
|
|
|
30 |
2 |
p. 157-159
|
artikel
|
| 13 |
Improving our knowledge in PD-L1 testing in lung cancer: the archival sample is ‘promoted’!
|
Morabito, A.
|
|
|
30 |
2 |
p. 165-167
|
artikel
|
| 14 |
Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer
|
Wang, J.T.
|
|
|
30 |
2 |
p. 266-273
|
artikel
|
| 15 |
Is front-line checkpoint blockade ATTRACTIVE in advanced gastric cancer?
|
Cartwright, E.
|
|
|
30 |
2 |
p. 159-161
|
artikel
|
| 16 |
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study
|
Hong, D.S.
|
|
|
30 |
2 |
p. 325-331
|
artikel
|
| 17 |
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer
|
Seiwert, T.Y.
|
|
|
30 |
2 |
p. 297-302
|
artikel
|
| 18 |
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
|
Urbonas, V.
|
|
|
30 |
2 |
p. 317-324
|
artikel
|
| 19 |
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
|
Wu, Y.-L.
|
|
|
30 |
2 |
p. 171-210
|
artikel
|
| 20 |
Pathological grade-independent prediction of chemosensitivity by CINSARC should rehabilitate adjuvant chemotherapy in soft tissue sarcomas of any grade
|
Bertucci, F.
|
|
|
30 |
2 |
p. 342-343
|
artikel
|
| 21 |
Patient-reported outcomes (PROs) as a routine measure for cancer inpatients: the final missing piece of the puzzle?
|
Brandt, J.
|
|
|
30 |
2 |
p. 167-169
|
artikel
|
| 22 |
Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051)
|
Lockhart, A.C.
|
|
|
30 |
2 |
p. 345
|
artikel
|
| 23 |
Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma
|
Inwards, D.J.
|
|
|
30 |
2 |
p. 346
|
artikel
|
| 24 |
Pilot randomized trial of an electronic symptom monitoring intervention for hospitalized patients with cancer
|
Nipp, R.D.
|
|
|
30 |
2 |
p. 274-280
|
artikel
|
| 25 |
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)
|
Peters, S.
|
|
|
30 |
2 |
p. 161-165
|
artikel
|
| 26 |
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
|
Luen, S.J.
|
|
|
30 |
2 |
p. 236-242
|
artikel
|
| 27 |
Reply to letters to the editor by Brentisci et al. and Consonni and Mensi
|
Boffetta, P.
|
|
|
30 |
2 |
p. 341
|
artikel
|
| 28 |
Reply to the letter to the Editor "Reply to 'Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists' by H. A. Haenssle et al. " by L. Oakden-Rayner
|
Haenssle, H.A.
|
|
|
30 |
2 |
p. 339
|
artikel
|
| 29 |
REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients
|
Shitara, K.
|
|
|
30 |
2 |
p. 259-265
|
artikel
|
| 30 |
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
|
Boku, N.
|
|
|
30 |
2 |
p. 250-258
|
artikel
|
| 31 |
Table of Contents
|
|
|
|
30 |
2 |
p. iv-vi
|
artikel
|
| 32 |
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial
|
Herbst, R.S.
|
|
|
30 |
2 |
p. 281-289
|
artikel
|
| 33 |
Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium
|
Webb, P.M.
|
|
|
30 |
2 |
p. 310-316
|
artikel
|
Tijdschrift beschrijving